Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtriCure, Inc. (ATRC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. AtriCure is a Nasdaq Global Market registrant whose common stock is listed under the symbol ATRC, and its filings offer detailed information on financial performance, capital structure, and material corporate events.
Investors can review Form 8-K current reports in which AtriCure discloses items such as preliminary and quarterly financial results, amendments to its Credit Agreement, and the creation of direct financial obligations. For example, recent 8-K filings describe an amendment to the company’s asset-based revolving credit facility with JPMorgan Chase Bank, N.A., including an extension of the term, a reduction in the overall interest rate, and changes to certain covenants. Other 8-Ks furnish press releases detailing revenue by product category and geography, non-GAAP metrics like adjusted EBITDA and adjusted loss per share, and commentary on operating trends.
Through its periodic reports and related exhibits, AtriCure outlines balance sheet data, income statement details, and non-GAAP reconciliations. These materials help readers understand how the company reports revenue from open ablation, minimally invasive ablation, pain management, and appendage management, as well as its research and development and selling, general, and administrative expenses. The filings also describe the structure and collateral of the ABL Facility, including the security interest in the assets of the borrowers and guarantees by material domestic subsidiaries.
On this page, Stock Titan enhances access to AtriCure’s filings with AI-powered summaries that explain the key points of lengthy documents such as 8-Ks and, when available, 10-Q and 10-K reports. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated highlights can help users quickly identify important changes in credit agreements, financial guidance, or operating results without reading every line of the original filing.
For those tracking ATRC, this filings hub is a central resource for analyzing the company’s disclosed financial condition, capital arrangements, and significant events as reported in its official SEC documents.
Wellington Management filed a Schedule 13G reporting beneficial ownership of AtriCure, Inc. common stock on behalf of clients. The reporting group indicates 3,969,269 shares, representing 8.02% of the class. Across the reporting entities, shared voting power is reported as 2,342,505 votes and shared dispositive power as 3,969,269 shares, while one entity lists shared dispositive power of 3,377,947 and a cover-page percent of 6.8% under its entry.
The filing states these securities are owned of record by clients of Wellington's investment advisers and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. Reporting entities are identified as holding companies (HC) and investment advisers (IA) under the applicable rules.
Michael H. Carrel, who serves as President, CEO and a Director of AtriCure, reported a charitable gift of 10,000 shares of AtriCure common stock on 08/08/2025 with no consideration received. After the reported transaction he beneficially owned 697,377 shares directly. The filing also discloses that 9,310 shares are held by his children and 2,250 shares are held by his parents, which he disclaims except for a pecuniary interest. The disclosure is coded as a gift and reflects insider compliance with Section 16 reporting.
AtriCure, Inc. (ATRC) Form 4: Director Regina E. Groves sold 2,452 common shares on 08-06-2025 at a weighted-average price of $36.82, a transaction valued at roughly $90 k.
After the sale, Groves directly owns 33,715 shares. No derivative securities were involved and the filing does not cite a Rule 10b5-1 trading plan. There are no disclosures of additional insider transactions, compensation changes, or company events in this filing.
The reported sale reduced her direct position by about 6.8% (from 36,167 to 33,715 shares). While a single Form 4 offers limited context, investors often track insider activity as a sentiment gauge. This transaction is modest relative to AtriCure’s average daily volume and does not, by itself, indicate a change in corporate fundamentals.
On this Form 4, AtriCure (ATRC) Chief Scientific Officer Vinayak S. Doraiswamy reported an open-market sale of 2,500 common shares on 08/05/2025 at $36.58 per share, yielding roughly $91 K in proceeds. After the transaction, he directly owns 71,872 shares, down about 3.4% from 74,372, leaving a stake worth ~$2.6 M at the sale price. No derivative trades were disclosed, and the filing cites no Rule 10b5-1 plan. Aside from this single sale, the document contains no financial results, guidance, or additional corporate events.
AtriCure, Inc. (ATRC) – Form 144 filing
- Proposed sale: 2,452 common shares (≈0.005% of the 49.7 million shares outstanding).
- Estimated value: US$90,307 based on market price at filing.
- Selling party: Not identified; shares held for the account of an insider who received them as a stock-award (compensation) on 05/20/2021.
- Broker: Fidelity Brokerage Services LLC.
- Planned trade date: on or after 08/06/2025; exchange: NASDAQ.
- No other ATRC shares have been sold by this person in the past three months.
The notice is procedural under Rule 144 and involves a de-minimis volume relative to total float. It has no dilution effect and signals only a routine insider liquidity event. Investors typically view such a small Form 144 filing as neutral and non-material to valuation or governance considerations.
On 30 Jul 2025 AtriCure, Inc. ("ATRC") filed a Form S-8 with the SEC to register 1,700,000 additional shares of common stock for issuance under its 2023 Stock Incentive Plan. Because the company is a large accelerated filer, the shares become eligible for grant immediately upon effectiveness.
The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and a recent Form 8-K, and includes standard undertakings and indemnification language. Keating Muething & Klekamp PLL supplied the legal opinion, while Deloitte & Touche LLP provided the auditor’s consent. No new financial statements, pricing terms or selling shareholder information are presented.
The registration expands the equity pool used to attract, retain and motivate employees and directors; however, issuance of the newly registered shares could dilute existing shareholders when awards vest or are exercised.
AtriCure (ATRC) Q2-25 10-Q highlights: Revenue rose 17.1% YoY to $136.1 M, driven by 41% growth in Pain Management and 19% in Appendage Management; Minimally Invasive Ablation fell 34%. International sales advanced 23% (20% cc). Six-month revenue reached $259.8 M, +15.4% YoY.
Gross margin held at 74.5%. Operating loss narrowed to $6.2 M from $7.2 M; net loss improved to $6.2 M (-$0.13 EPS) vs. $8.0 M (-$0.17). YTD net loss nearly halved to $12.9 M. Cash flow from operations swung to +$10.6 M (vs. -$13.6 M). Cash & equivalents ended at $117.8 M; long-term ABL debt unchanged at $61.9 M, leaving $61.9 M in unused capacity.
R&D expense jumped 43% to $29.3 M, including a $5 M milestone for the pulsed-field ablation (PFA) Cooperation Agreement. SG&A rose 6.5% on headcount. Key milestones: FDA 510(k) clearances for AtriClip PRO-Mini and cryoICE cryoXT (launches 2H-25); completion of 6,500-patient LeAAPS stroke-prevention trial enrollment.
Risk factors: a Delaware suit from former SentreHEART holders seeks up to $260 M over PMA milestone; management deems loss not probable/estimable. Minimally invasive revenue weakness and flat margins bear monitoring.